Physician profile
Robert Bates Taylor
NPI 1851633382
$2,343.59
in general payments reported to CMS, 2019-2025
21 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $186 · 2021: $134 · 2022: $313 · 2023: $258 · 2024: $437 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.93 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Scientific Affairs, LLC | $149.26 | 2025 | Tremfya |
| Micro-Tech Endoscopy USA, INC. | $135.65 | 2021-2022 | |
| Celgene Corporation | $134.57 | 2022-2023 | Zeposia |
| Pfizer INC. | $132.32 | 2025 | |
| Janssen Biotech, INC. | $130.18 | 2024-2025 | Tremfya |
| Echosens North America, INC. | $125.35 | 2024 | Fibroscan |
| E.R. Squibb & Sons, L.L.C. | $124.75 | 2022 | |
| Ardelyx, INC. | $112.06 | 2023-2025 | Ibsrela |
| Olympus Corporation of The Americas | $71.41 | 2019 | |
| Phathom Pharmaceuticals, INC. | $68.33 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $66.67 | 2022-2024 | Entyvio |
| Madrigal Pharmaceuticals | $49.36 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $24.11 | 2019 | |
| Boston Scientific Corporation | $21.30 | 2025 | Ams 700 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $19.99 | 2024 | Soliris |
| Rochester Medical Corporation | $19.23 | 2022 | |
| Astellas Pharma US INC | $17.78 | 2019 | |
| Aimmune Therapeutics, INC. | $14.76 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $13.88 | 2023 | Exparel, Iovera |
| Genzyme Corporation | $13.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.